Prevalence and modern aspects of the treatment of patients with Barrett’s esophagus
https://doi.org/10.21518/2079-701X-2018-14-24-27
Abstract
The article analyzes the prevalence and principles in treatment of Barrett’s esophagus. The prevalence of Barrett’s esophagus varies widely from region to region of the world and has ethnic differences. The use of endoscopic methods and the histological examination of the biopsies of esophageal mucosa are of utmost importance in the diagnosis of this pathology. The prevention of esophageal cancer is the main task in managing patients with Barrett’s esophagus. The length of the Barrett’s esophagus segment, the presence and extent of dysplasia is of the greatest importance to select tactics for managing patients. Endoscopic methods are widely used for the eradication of metaplasia sites, among which the radiofrequency ablation is the most effective one. Prolonged treatment with proton pump inhibitors is safe and reduces the risk of transformation of Barrett’s esophagus into adenocarcinoma of the esophagus. There is evidence that small doses of aspirin, nonsteroidal anti-inflammatory drugs, statins and ursodeoxycholic acid have the preventive effect on the development of esophageal cancer. However, the possibilities of using these drugs for this purpose are still limited. Anti-reflux surgery still holds relevance, but at the same time, it has no advantages over the drug therapy for the prevention of esophageal cancer.
About the Authors
V. V. Tsukanov
Federal Research Center “Krasnoyarsk Research Center” of the Siberian Branch of the Russian Academy of Sciences, a separate subdivision of Research Institute for Medical Problems in the North (NII MPS)
Russian Federation
Krasnoyarsk
Russian Federation
Krasnoyarsk
A. V. Vasyutin
Federal Research Center “Krasnoyarsk Research Center” of the Siberian Branch of the Russian Academy of Sciences, a separate subdivision of Research Institute for Medical Problems in the North (NII MPS)
Russian Federation
Krasnoyarsk
Russian Federation
Krasnoyarsk
N. N. Butorin
Remishevskaya Khakas Republican Hospital
Russian Federation
Abakan
Russian Federation
Abakan
Yu. L. Tonkikh
Federal Research Center “Krasnoyarsk Research Center” of the Siberian Branch of the Russian Academy of Sciences, a separate subdivision of Research Institute for Medical Problems in the North (NII MPS)
Russian Federation
Krasnoyarsk
Russian Federation
Krasnoyarsk
O. V. Peretyatko
Federal Research Center “Krasnoyarsk Research Center” of the Siberian Branch of the Russian Academy of Sciences, a separate subdivision of Research Institute for Medical Problems in the North (NII MPS)
Russian Federation
Krasnoyarsk
Russian Federation
Krasnoyarsk
A. S. Pulikov
Federal Research Center “Krasnoyarsk Research Center” of the Siberian Branch of the Russian Academy of Sciences, a separate subdivision of Research Institute for Medical Problems in the North (NII MPS)
Russian Federation
Krasnoyarsk
Russian Federation
Krasnoyarsk
References
1. Shaheen NJ, Falk GW, Iyer PG, Gerson LB. ACG Clinical Guideline: Diagnosis and Management of Barrett’s Esophagus. Am J Gastroenterol, 2016, 111(1): 30-50.
2. Fitzgerald RC, di Pietro M, Ragunath K, Ang Y, Kang JY, Watson P et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut, 2014, 63(1): 7-42.
3. Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett’s esophagus. Am J Gastroenterol, 2008, 103(3): 788-797.
4. Tsukanov VV, Onuchina EV, Vasyutin AV, Butorin NN, Amelchugova OS. Clinical aspects of gastroesophageal reflux disease in the elderly: the 5-year prospective study results. Terapevtichesky Arkhiv, 2014, 86 (2): 23-26.
5. Tsukanov VV, Amelchugova OS, Kasparov EV, Butorin NN, Vasyutin AV, Tonkikh YuL, Tretyakova OV. The role of Helicobacter pylori eradication in the prevention of gastric cancer. Terapevtichesky Arkhiv, 2014, 86 (8): 124-127.
6. Rajendra S, Sharma P. Barrett Esophagus and Intramucosal Esophageal Adenocarcinoma. Hematol Oncol Clin North Am, 2017, 31(3): 409- 426.
7. Cook MB, Coburn SB, Lam JR, Taylor PR, Schneider JL, Corley DA. Cancer incidence and mortality risks in a large US Barrett’s oesophagus cohort. Gut, 2018, 67(3): 418-529.
8. Coleman HG, Xie SH, Lagergren J. The Epidemiology of Esophageal Adenocarcinoma. Gastroenterology, 2018, 154(2): 390-405.
9. Rex DK, Cummings OW, Shaw M, Cumings MD, Wong RK, Vasudeva RS et al. Screening for Barrett’s esophagus in colonoscopy patients with and without heartburn. Gastroenterology, 2003, 125(6): 1670-1677.
10. Zagari RM, Fuccio L, Wallander MA, Johansson S, Fiocca R, Casanova S et al. Gastrooesophageal reflux symptoms, oesophagitis and Barrett’s oesophagus in the general population: the Loiano-Monghidoro study. Gut, 2008, 57(10): 1354-1359.
11. Shiota S, Singh S, Anshasi A, El-Serag HB. Prevalence of Barrett’s Esophagus in Asian Countries: A Systematic Review and Metaanalysis. Clin Gastroenterol Hepatol, 2015, 13(11): 1907-1918.
12. Ageeva ES, Shtygasheva OV, Ryazantseva NV, Tsukanov VV. Molecular genetic factors that influence the outcomes of Helicobacter pylori infection in the Republic of Khakassia population. Rossiyskiy Zhurnal Gastroenterologii, Gepatologii, Koloproktologii, 2010, 20 (4): 16-21.
13. Butorin NN, Bichurina TB, Tsukanov VV, Kasparov EV, Kuklin DV, Timoshenko VO, et al. The prevalence and clinical aspects of Barrett’s esophagus among the Eastern Siberia population. Terapevtichesky Arkhiv, 2013, 85 (1): 62-65
14. Weusten B, Bisschops R, Coron E, Dinis-Ribeiro M, Dumonceau JM, Esteban JM et al. Endoscopic management of Barrett’s esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. Endoscopy, 2017, 49(2): 191-198.
15. Whiteman DC, Appleyard M, Bahin FF, Bobryshev YV, Bourke MJ, Brown I et al. Australian clinical practice guidelines for the diagnosis and management of Barrett’s esophagus and early esophageal adenocarcinoma. J Gastroenterol Hepatol, 2015, 30(5): 804-820.
16. Fock KM, Talley N, Goh KL, Sugano K, Katelaris P, Holtmann G et al. Asia-Pacific consensus on the management of gastro-oesophageal reflux disease: an update focusing on refractory reflux disease and Barrett’s oesophagus. Gut, 2016, 65(9): 1402-1415.
17. Clermont M, Falk GW. Clinical Guidelines Update on the Diagnosis and Management of Barrett’s Esophagus. Dig Dis Sci, 2018, Apr 18 [Epub ahead of print], doi: 10.1007/s10620- 018-5070-z.
18. Findlay JM, Middleton MR, Tomlinson I. Genetic Biomarkers of Barrett’s Esophagus Susceptibility and Progression to Dysplasia and Cancer: A Systematic Review and Meta-Analysis. Dig Dis Sci, 2016, 61(1): 25-38.
19. Sharma P, Dent J, Armstrong D, Bergman JJ, Gossner L, Hoshihara Y et al. The development and validation of an endoscopic grading system for Barrett’s esophagus: the Prague C & M criteria. Gastroenterology, 2006, 131(5): 1392-1399.
20. Pohl H, Pech O, Arash H, Stolte M, Manner H, May A et al. Length of Barrett’s oesophagus and cancer risk: implications from a large sample of patients with early oesophageal adenocarcinoma. Gut, 2016, 65(2): 196-201.
21. Rajendra S, Sharma P. Barrett’s Esophagus. Curr Treat Options Gastroenterol, 2014, 12(2): 169-182.
22. Pandey G, Mulla M, Lewis WG, Foliaki A, Chan DSY. Systematic review and meta-analysis of the effectiveness of radiofrequency ablation in low grade dysplastic Barrett’s esophagus. Endoscopy, 2018, Apr 24, [Epub ahead of print], doi: 10.1055/a-0588-5151.
23. Singh S, Garg SK, Singh PP, Iyer PG, El-Serag HB. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett’s oesophagus: a systematic review and meta-analysis. Gut, 2014, 63(8): 1229-1237.
24. Freedberg DE, Kim LS, Yang YX. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. Gastroenterology, 2017, 152(4): 706-715.
25. Liao LM, Vaughan TL, Corley DA, Cook MB, Casson AG, Kamangar F et al. Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis. Gastroenterology, 2012, 142(3): 442-452.
26. Tsukanov VV, Onuchina EV, Kasparov EV, Vasyutin AV, Tonkikh YuL. The experience of prolonged therapy of patients with Barrett’s esophagus. Pharmateca, 2015, 2: 62-65
27. Wassenaar EB, Oelschlager BK. Effect of medical and surgical treatment of Barrett’s metaplasia. World J Gastroenterol, 2010, 16(30): 3773-3779.
28. Rayner CJ, Gatenby P. Effect of antireflux surgery for Barrett’s esophagus: long-term results. Minerva Chir, 2016, 71(3): 180-191.
Review
For citations:
Tsukanov VV, Vasyutin AV, Butorin NN, Tonkikh YL, Peretyatko OV, Pulikov AS. Prevalence and modern aspects of the treatment of patients with Barrett’s esophagus. Meditsinskiy sovet = Medical Council. 2018;(14):24-27. (In Russ.) https://doi.org/10.21518/2079-701X-2018-14-24-27
Views:
651
Email this article 